Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:AVTE NASDAQ:ICCC NASDAQ:SGMT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.91-2.1%$1.77$1.05▼$5.17$211.25M0.27845,909 shs2.04 million shsAVTEAerovate Therapeutics$7.42-3.8%$7.84$56.35▼$105.00$215.07M0.9512,438 shs189,557 shsICCCImmuCell$5.96+5.3%$6.30$3.38▼$7.60$51.20M0.297,015 shs12,087 shsSGMTSagimet Biosciences$6.52-3.4%$8.13$1.73▼$11.41$219.52M3.34454,116 shs621,943 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-2.05%-2.05%+5.52%+31.72%+63.25%AVTEAerovate Therapeutics+10.94%-0.64%+4.76%-22.04%-88.47%ICCCImmuCell+5.30%+0.68%-1.24%-21.58%+65.56%SGMTSagimet Biosciences-3.41%-3.55%-9.19%-25.23%+92.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$1.91-2.1%$1.77$1.05▼$5.17$211.25M0.27845,909 shs2.04 million shsAVTEAerovate Therapeutics$7.42-3.8%$7.84$56.35▼$105.00$215.07M0.9512,438 shs189,557 shsICCCImmuCell$5.96+5.3%$6.30$3.38▼$7.60$51.20M0.297,015 shs12,087 shsSGMTSagimet Biosciences$6.52-3.4%$8.13$1.73▼$11.41$219.52M3.34454,116 shs621,943 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics-2.05%-2.05%+5.52%+31.72%+63.25%AVTEAerovate Therapeutics+10.94%-0.64%+4.76%-22.04%-88.47%ICCCImmuCell+5.30%+0.68%-1.24%-21.58%+65.56%SGMTSagimet Biosciences-3.41%-3.55%-9.19%-25.23%+92.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.11Buy$8.71356.25% UpsideAVTEAerovate Therapeutics 0.00N/AN/AN/AICCCImmuCell 0.00N/AN/AN/ASGMTSagimet Biosciences 3.00Buy$25.67293.66% UpsideCurrent Analyst Ratings BreakdownLatest ICCC, SGMT, AVTE, and ACRS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/11/2025SGMTSagimet BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$28.008/7/2025SGMTSagimet BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$29.007/24/2025SGMTSagimet BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.007/10/2025ACRSAclaris TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.006/25/2025ACRSAclaris TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.006/23/2025ACRSAclaris TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$8.00(Data available from 9/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$18.72M11.05N/AN/A$1.44 per share1.33AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AICCCImmuCell$26.49M2.04$0.07 per share88.03$3.09 per share1.93SGMTSagimet Biosciences$2M106.02N/AN/A$5.08 per share1.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$132.07M-$1.37N/AN/AN/A-802.03%-34.01%-24.18%11/5/2025 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)ICCCImmuCell-$2.16M$0.1931.37∞N/A6.23%6.25%3.87%11/12/2025 (Estimated)SGMTSagimet Biosciences-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%11/13/2025 (Estimated)Latest ICCC, SGMT, AVTE, and ACRS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ICCCImmuCellN/A$0.06N/A$0.06N/A$6.45 million8/13/2025Q2 2025SGMTSagimet Biosciences-$0.52-$0.32+$0.20-$0.32N/AN/A8/7/2025Q2 2025ACRSAclaris Therapeutics-$0.13-$0.13N/A-$0.13$1.34 million$1.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AICCCImmuCellN/AN/AN/AN/AN/ASGMTSagimet BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A3.883.88AVTEAerovate TherapeuticsN/A8.788.78ICCCImmuCell0.283.851.99SGMTSagimet BiosciencesN/A17.5517.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%AVTEAerovate TherapeuticsN/AICCCImmuCell13.47%SGMTSagimet Biosciences87.86%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics5.60%AVTEAerovate Therapeutics24.90%ICCCImmuCell5.60%SGMTSagimet Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100108.33 million102.27 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableICCCImmuCell709.05 million8.54 millionNot OptionableSGMTSagimet Biosciences832.52 million27.74 millionOptionableICCC, SGMT, AVTE, and ACRS HeadlinesRecent News About These CompaniesSagimet Biosciences Inc. (NASDAQ:SGMT) Receives $25.67 Average PT from AnalystsSeptember 19 at 3:49 AM | americanbankingnews.comSagimet Biosciences reports data from Phase 3 trial on denifanstatSeptember 17 at 11:30 PM | msn.comPositive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner AscletisSeptember 17 at 7:00 AM | globenewswire.comHere's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 WeeksSeptember 16, 2025 | zacks.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 16, 2025 | marketbeat.comWall Street Zen Downgrades Sagimet Biosciences (NASDAQ:SGMT) to SellSeptember 15, 2025 | marketbeat.comSagimet Biosciences (NASDAQ:SGMT) Lowered to "Sell" Rating by Wall Street ZenSeptember 14, 2025 | americanbankingnews.comSagimet Biosciences announces presentations at MASH Drug Development SummitSeptember 10, 2025 | msn.comSagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development SummitSeptember 10, 2025 | globenewswire.comAlyeska Investment Group L.P. Sells 98,069 Shares of Sagimet Biosciences Inc. $SGMTSeptember 8, 2025 | marketbeat.comWall Street Zen Upgrades Sagimet Biosciences (NASDAQ:SGMT) to "Hold"September 8, 2025 | marketbeat.comSagimet Biosciences Inc. (SGMT) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 7, 2025 | seekingalpha.comSagimet Biosciences: Strong Denifanstat Pipeline Progress, Funding Overhang Keeps Stock At HoldAugust 31, 2025 | seekingalpha.comSagimet Gains Momentum As FDA Eases Path For MASH Drug DevelopmentAugust 29, 2025 | seekingalpha.comSagimet Biosciences to Participate in Two Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.comSagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by BrokeragesAugust 21, 2025 | marketbeat.comSagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?August 20, 2025 | zacks.comAfter Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)August 20, 2025 | zacks.comSagimet Biosciences Enters New Sales Agreement with LeerinkAugust 15, 2025 | msn.comSagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 13, 2025 | finanznachrichten.deSagimet Biosciences Tops Q2 EPS ForecastAugust 13, 2025 | aol.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeICCC, SGMT, AVTE, and ACRS Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$1.91 -0.04 (-2.05%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$1.88 -0.03 (-1.57%) As of 09/19/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Aerovate Therapeutics NASDAQ:AVTE$7.42 -0.29 (-3.76%) As of 09/19/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.ImmuCell NASDAQ:ICCC$5.96 +0.30 (+5.30%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$5.98 +0.03 (+0.42%) As of 09/19/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.Sagimet Biosciences NASDAQ:SGMT$6.52 -0.23 (-3.41%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.52 0.00 (0.00%) As of 09/19/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock Tesla: 2 Reasons to Love Musk's $1B Buy, 1 Reason to Be Bearish Berkshire-Backed Lennar Slides After Weak Q3 Earnings Azure Leads While AI Excitement Fuels Microsoft Stock Caterpillar Stock Hits All-Time High—Is There More Room to Run? The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Darden Restaurants: A Textbook Buy-the-Dip Opportunity McDonald’s: New All-Time Highs Are Inevitable Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
